Auransa to Participate in BioCentury-BayHelix China Healthcare Summit 2019
November 12, 2019 08:05 ET
|
Auransa
PALO ALTO, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Auransa, Inc., an artificial intelligence (AI)-driven pharmaceutical company developing precision medicines in areas of significant unmet medical...
Auransa Presents New Preclinical Data on AU-409, a Novel, AI-Derived Drug Candidate for the Treatment of Hepatocellular Carcinoma
September 23, 2019 08:05 ET
|
Auransa
PALO ALTO, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Auransa Inc., an artificial intelligence (AI)-driven biotechnology company developing precision medicines in areas of significant unmet medical...
Celsion Co-sponsors Hepatocellular Carcinoma Symposium at the International Liver Cancer Association (ILCA) Annual Conference
September 23, 2019 08:00 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces it co-sponsored a symposium focused on hepatocellular...
Auransa to Present New Data on AU-409, a Novel, AI-Generated Drug Candidate for the Treatment of Hepatocellular Carcinoma, at the 13th Annual Conference of the International Liver Cancer Association
September 16, 2019 08:05 ET
|
Auransa
PALO ALTO, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Auransa Inc., an artificial intelligence (AI)-driven biotechnology company developing precision medicines in areas of significant unmet medical...
Auransa Announces CEO to Participate on Executive Leadership Panel at the 6th Annual Indy Big Data Conference
September 12, 2019 08:05 ET
|
Auransa
PALO ALTO, Calif., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Auransa Inc., an artificial intelligence (AI)-driven biotechnology company developing precision medicines in areas of significant unmet medical...
Celsion Announces Publication of Findings from Single-Site Study in China of ThermoDox® Plus RFA in the Journal of Cancer Research and Therapeutics
August 27, 2019 08:00 ET
|
Celsion CORP
Data show overall survival improvement of 22.5 months with ThermoDox® plus RFA of 45 minutes or longer Data provides additional corroboration of ThermoDox’s potential for superior efficacy when...
Celsion Announces Data Lock for First Interim Analysis in OPTIMA Phase III Study of ThermoDox® in Primary Liver Cancer
August 05, 2019 09:00 ET
|
Celsion CORP
Independent Data Monitoring Committee to Meet in October to Evaluate Interim Trial Data LAWRENCEVILLE, N.J., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology...
CloudMedx Working With UCSF to Deploy AI Tools to Support the Management of Liver Cancer Patients Awaiting Liver Transplant
August 02, 2018 17:21 ET
|
CloudMedx Inc.
PALO ALTO, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- CloudMedx, a healthcare AI company that provides real time and actionable insights to the healthcare industry, today announced it is working with...
Therapeutic Solutions International, Inc., Appoints Juergen Winkler, MD, ABIHM to Scientific Advisory Board
July 09, 2018 09:00 ET
|
Therapeutic Solutions International, Inc.
Pioneer of Functional Medicine Teams Up with Clinical Stage Biotechnology Company in Commercialization of Non-Toxic Immunotherapy OCEANSIDE, Calif., July 09, 2018 (GLOBE NEWSWIRE) -- Via OTC PR...
ArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of Tivantinib in Second-Line Hepatocellular Carcinoma at the 2016 Gastrointestinal Cancers Symposium
January 25, 2016 07:30 ET
|
ArQule, Inc.
Preliminary analysis of baseline MET incidence in METIV-HCC trial confirms results observed in phase 2 trial BURLINGTON, Mass., Jan. 25, 2016 (GLOBE NEWSWIRE) -- ArQule, Inc. (NASDAQ:ARQL)...